

Micom: metagenome-scale modeling to infer metabolic interactions in the microbiota.

Christian Diener^{1,2} and Osbaldo Resendis-Antonio^{1,3,*}.

¹ Instituto Nacional de Medicina Genómica (INMEGEN), Mexico City 14610, México

² Institute for Systems Biology, Seattle, WA, USA

³ Human Systems Biology Laboratory. Coordinación de la Investigación Científica - Red de Apoyo a la Investigación, UNAM.

* Corresponding author: oresendis@inmegen.gob.mx

Abstract

Alterations in the gut microbiota have been associated with a variety of medical conditions such as obesity, Crohn's disease and diabetes. However, establishing connections between the microbial composition and function remains a challenge. We introduce a strategy based on metabolic models of complete microbial gut communities and apply it to derive the particular metabolic consequences of the microbial composition for the diabetic gut in a balanced cohort of 186 individuals. By using a heuristic optimization approach based on L2 regularization we were able to obtain a unique set of realistic growth rates that allows growth for the majority of observed taxa in a sample. We also integrated various additional constraints such as diet and the measured abundances of microbial species to derive the resulting metabolic alterations for individual metagenomic samples. In particular, we show that growth rates vary greatly across samples and that there exists a network of bacteria implicated in health and disease that mutually maintain each other's growth rates. Studying individual exchange fluxes in the gut microbiota we observed that consumption of metabolites by the microbiota follows a niche structure whereas production of short chain fatty acids by the microbiota was highly sample-specific, showed complex cross-feeding, and was affected in diabetes. In particular the models predicted alterations in SCFA production in Danish individuals and its restoration after metformin treatment. Additionally, we found that production of many metabolites by the microbiota could not be easily influenced by single-target interventions and that intervention effects may be very different across individuals. All methods are implemented in the open source Python package "micom" which is available at <https://github.com/resendislab/micom>.

34

35 Introduction

36 The microbial composition in the gut may be highly consequential for human metabolism
37 and has been associated to a variety of medical conditions such as obesity, Crohn's Disease,
38 diabetes and colorectal cancer (1–5). Nevertheless, the causality by which the microbiota may
39 alter the host's metabolism remains unclear. Several studies have mapped microbial genes in
40 the microbiome to particular functions (6–8), however that approach is only qualitative since the
41 presence of a particular metabolic gene does not guarantee expression nor a change in the
42 associated biochemical reaction. An alternative strategy to quantify the metabolic alterations
43 that microbial community can induce in the host' metabolism is to use computational models for
44 analyzing the fluxes in biochemical networks (9, 10). Even though direct measurement of fluxes
45 by carbon or nitrogen labeling is costly, one can usually approximately infer the metabolic fluxes
46 of a particular model organism using genome-scale metabolic models. For individual bacteria,
47 metabolic modeling using flux balance analysis (FBA) has shown to be a valuable tool to
48 explore their respective metabolic capacities and has been used extensively in basic research,
49 biochemical strain design and in vitro models of bacterial interactions (11–14). In FBA, fluxes
50 are usually approximated from a genome-scale model containing all known biochemical
51 reactions by maximizing the production of biomass under various constraints mirroring the
52 enzymatic, thermodynamic and environmental conditions (12). For instance, one can restrict
53 metabolic import fluxes to the ones whose substrate is present in (11, 13, 15) the media in order
54 to simulate a particular growth medium. Extending FBA to microbial communities can be
55 challenging due to the necessity of modeling the metabolic exchanges between individuals and
56 suggesting a proper objective function to mimic the growth of the entire community as well as
57 individual bacterial species.

58 In many cases one only maximizes the overall growth rate of the entire community which
59 may be problematic since individual species might be competitive and will rather maximize their
60 own growth rate than the growth rate of the community. More complex methods such as
61 OptCom thus try to find the joint multi-objective maximum of the individual and community
62 growth rates (16). However, those multi-objective methods are limited to communities consisting
63 of only very few members which is not realistic for microbial communities in the gut which may
64 contain up to several hundred distinct subpopulations (17). An additional challenge is the
65 inclusion of abundance data obtained from 16S rRNA sequencing or metagenomic shotgun

66 experiments into the metabolic model. This is particularly important for the metabolic exchanges
67 taking place between different species in the same community. A highly abundant species may
68 usually import and export much higher absolute quantities than a low abundant species which
69 will affect the resulting biochemical fluxes. Nevertheless, genome-scale metabolic modeling
70 shows a strong potential in microbial communities as it may directly quantify the metabolic
71 potential of a particular gut microbiota in the form of the metabolic fluxes. In particular, this
72 computational approach predicts the metabolic exchange rates between the host and the
73 microbial community in the gut which suggests possible mechanisms associated with the
74 wellness or disease state of the host.

75 In this work, we present a strategy that efficiently extends metabolic modeling to
76 microbial communities. Using an iterative strategy of linear and quadratic optimizations over a
77 community of microbial genome scale metabolic reconstructions, we were able to scale a
78 formulation that uses the community as well as individual growth to several hundred microbial
79 species which enables the study of realistic microbial compositions. Additionally, we explicitly
80 included microbial abundances from metagenomic shotgun sequencing and realistic diets in
81 order to make quantitative predictions regarding the metabolic consequences for the host. The
82 entire strategy is implemented in an easy to use Python software package called “micom”. In
83 order to assess the explicative and predictive capacities of our approach, we applied the
84 analysis in micom to a balanced data set of 186 Danish and Swedish individuals distributed
85 across healthy individuals, patients with type 1 diabetes and patients with type 2 diabetes (with
86 and without metformin treatment). We show that individual bacterial growth rates vary greatly
87 across samples and that a subset of bacteria often associated with health show strong
88 interdependencies within samples. We also quantified exchanges between the gut microbiota
89 and gut lumen and studied the effect of the microbiota composition on the production of short
90 chain fatty acids (SCFAs) across samples from healthy and diabetic individuals.

91

92

93

94

95

96

97 Results

98 A regularization strategy for microbial community models.

99

100 Growth in microbial communities can be quantified by two classes of growth rates, the
101 community growth rate μ_c (in 1/h) which expresses the growth of the entire community and the
102 individual growth rates μ_i which measures the growth of the subpopulation i (16, 18). Here, the
103 community growth rate μ_c is connected to the individual growth rates μ_i by

104

$$105 \mu_c = \sum_i a_i \mu_i \quad (1)$$

106

107 where a_i denote the relative abundance for the subpopulation i (the fraction of the community
108 that is constituted by this subpopulation). Even though FBA can be used to obtain the maximum
109 community growth rate, one can see from equation 1 that there is an infinite combination of
110 different individual growth rates μ_i for any given community growth rate μ_c (see Figure 1A for an
111 example). Various strategies have been employed in order to deal with this limitation, the most
112 common one being just reporting any one of the possible growth rates distributions for μ_i . Other
113 approaches have tried to find the set of growth rates that maximize community growth and
114 individual growth at the same time (16), but this is computationally intensive and may not scale
115 well to the gut microbiota which is composed by at least tens of different genera and hundreds
116 of different species (17, 19). Thus, we tried to formulate a strategy that would allow us to identify
117 a realistic set of individual growth rates μ_i and which would still scale to large communities. The
118 simplest case of a microbial community is a community composed of two identical clonal
119 subpopulations of the same bacterial strain each being present in the same abundance (thus
120 constituting 50% of the community each). Assuming that the maximum community and
121 individual growth rates are equal to one there are now many alternative solutions giving
122 maximal community growth as shown in Figure 1A. However, the two populations are identical
123 one would expect that both grown at the same rate. In order to enforce a particular distribution
124 of individual growth rates one can try to optimize an additional function over the individual
125 growth rates μ_i . This is known as regularization and the two most common strategies are L1
126 regularization which minimizes the sum of individual growth rates and L2 regularization which
127 minimized the sum of squares of the growth rates (20, 21). Here, only the L2 norm correctly
128 identifies the alternative solution where both subpopulations grow at the same rate as optimal.

129 The same strategy can be applied to heterogeneous microbial communities composed of
130 several subpopulations with different abundances. Here the L2 norm will give the distribution of
131 growth rates where growth is distributed as evenly as possible across the individual populations,
132 which allows growth for as many sub-populations as possible. Thus, the L2 norm minimization
133 can be interpreted as a heuristic for the simultaneous maximization of individual growth rates
134 attempted in the non-convex multi-objective formulation. This is also consistent with the demand
135 that a subpopulation observed in the gut microbiota should be able to grow in the gut.
136 Additionally, the L2 norm has a unique minimum. Thus, there is only one configuration of
137 individual growth rates μ_i that minimizes the L2 norm for a given community growth rate μ_c . In
138 practice, maximal community growth might only be achievable if many subpopulations are
139 excluded from growth, for instance by giving all resources to a fast growing subpopulation.
140 Again, this would be inconsistent if one has prior knowledge that the other subpopulations are
141 present in the gut and should be able to grow. Instead of enforcing the maximal community
142 growth rate one can limit community growth to only a fraction of its maximal rate. Thus, creating
143 a tradeoff between optimal community growth and individual growth rate maximization. Because
144 the community growth maximization requires full cooperativity whereas the L2 norm
145 minimization represents egoistic individual growth maximization, we call the two-step strategy to
146 fix the community growth rate a fraction of its optimum followed by minimization of the L2 norm
147 of individual growth rates “cooperative trade-off”.

148

149 Regularization by cooperative trade-off yields realistic growth rate
150 estimates.

151

152 In order to test whether cooperative trade-off yields realistic growth rates, we implemented and
153 applied it to a set of 186 samples from Swedish and Danish individuals (22), consisting of
154 healthy individuals, individuals with type 1 diabetes and individuals with type 2 diabetes
155 stratified by metformin treatment (a known modulator of gut microbiome). Relative abundances
156 for a total of 367 bacterial genera and 727 species were obtained with SLIMM (23) from
157 previously published metagenomic reads (22, 23) as described in the Methods section.
158 Abundance profiles for all identified genera across all samples were connected with the AGORA
159 models, a set of previously published manually curated metabolic models for 773 bacterial
160 species (24). In the used data set the AGORA reconstructions mapped to 109 genera which

161 represented more than 99% of the total abundance of the metagenomic reads with an assigned
162 genus (85.3% vs 85.7%, see Table 1) and in average 85% of all aligned reads for each sample.
163 Even though the cooperative tradeoff strategy is applicable to species-level subpopulations, the
164 AGORA reconstructions accounted in average only for 63% of the total reads in each sample
165 and for less than 50% of the total reads in some samples meaning that the AGORA models
166 would not be representative for the microbial diversity in those samples. Thus, we decided to
167 model the subpopulations at the genus level since this covers a larger fraction of the observed
168 microbiota. For that individual species models from AGORA were pooled into genus-level
169 models (see Methods). The resulting communities contained between 22 and 78 genera, each
170 represented by a full genome-scale metabolic model and connected by exchange reactions with
171 the gut lumen, thus yielding a set of 186 complete metagenome-scale metabolic models. We
172 used the relative read abundances as a proxy for the abundance of each genus in each sample
173 (see Methods). Even though DNA quantity is not an exact representation of bacterial mass (in
174 grams dry weight), we argue that the discrepancy between the two is probably much smaller
175 than the variation in abundances which spans several orders of magnitude (17). Import fluxes
176 for external metabolites were restricted by applying an average western diet to each community
177 model (24).

178

taxa	unique taxa	assigned reads	with model
superkindom	2	99.2% ± 1.5%	99.2% ± 1.5%
phylum	23	98.7% ± 1.5%	98.7% ± 1.5%
class	39	96.6% ± 1.9%	96.6% ± 1.9%
family	160	87.2% ± 3.8%	87.0% ± 3.9%
genus	367	85.7% ± 4.4%	85.3% ± 4.6%
species	727	68.3% ± 7.9%	63.6% ± 7.8%

179 Table 1: Distribution of taxa assignments across ranks. Shown are the number of unique taxa for each
180 rank together with the percentage of mapped reads that could be uniquely assigned to a taxa in the rank,
181 as well as the percentage of reads whose taxa had at least one representative in the AGORA genome-
182 scale metabolic models. Percentages are shown as mean ± standard deviation across the 186 samples.

183

184 We found that computation time generally scaled well with the community size when using
185 interior point methods which are known to provide better performance for larger models, with
186 most individual optimizations taking less than 5 minutes (25). However, we found that it was

187 difficult to maintain numerical stability with large community models. In fact, the largest difficulty
188 we encountered was numerical stability and not computation time. None of the tested solvers
189 were able to converge to optimality when solving the quadratic programming problem posed by
190 the L2 norm minimization (see Methods). Thus, we used a crossover strategy to identify an
191 optimal solution to the L2 minimization (see Methods).

192

193 For each of the of the 186 individual community models we solved several linear programming
194 problems in order to evaluate the effectiveness of different optimization strategies. First, to
195 establish a baseline we only maximized the community growth rate and used the arbitrary
196 distribution of growth rates that is returned by the solver when applying no regularization. This
197 was followed by applying the cooperative trade-off strategy with varying levels of suboptimality
198 ranging from 10% to 100% of the maximum community growth rate. As argued before we
199 observed that just optimizing the community growth rate with no regularization of the individual
200 growth rates led to solutions where only a few subpopulations were left to grow with
201 unreasonably high growth rates (doubling times smaller 5 minutes) whereas the rest of the
202 microbial community did not grow (compare Figures 1B-C with strategy marked by “none”).
203 Adding the L2 norm minimization even while maintaining maximum community growth notably
204 increased the growing fraction of the community and gave smaller growth rates overall.
205 However, we also found that maximization of the community growth rate is generally
206 incompatible with the assumption that the majority of the observed genera should be able to
207 grow. Lowering the community growth rate to suboptimal levels strongly increased the growing
208 fraction of the population where a community growth rate of 20% of its maximum will allow
209 essentially all bacterial subpopulations to grow. Based on reports that about 20-40% of the
210 bacteria found in stool are not viable (26), we chose a suboptimal community growth rate of
211 50% maximum growth (which allowed growth for about 70% of all subpopulations) as the trade-
212 off parameter for all subsequent analyses (see Figure S1).

213

214

215

216

217 Growth rates are heterogeneous and depend on the community 218 composition

219

220 The community and individual growth rates obtained this way were in good agreement with
221 previous evidence. Bacterial communities showed an average doubling time of about 10 hours
222 where individual genera had an average doubling time of 20 hours with a minimum of 23
223 minutes which is consistent with the generally low growth in the gut and the fast doubling time of
224 about 20 minutes that can be observed in laboratory growth media (27).

225

226 Even though community growth rates varied only little across all samples (0.069 +- 0.019 1/h)
227 we found that individual growth rates often varied across five orders of magnitude (see Figure
228 2). Here Eubacterium was predicted to be the fastest growing genus overall which is consistent
229 with the ubiquitous presence of Eubacterium in microbiome samples (28, 29). We found that
230 growth rates and abundances were not linearly correlated (Pearson R=0.0) but showed a
231 moderate correlation on the log-log scale (Pearson R=0.69) which indicates that the relationship
232 between abundance and growth rate weakly follows a Power law, Figure 3A. However, for any
233 given abundance growth rates would still vary by up to two orders of magnitude (compare
234 Figure 3A). Thus, the growth rate is related to abundance but cannot simply be inferred from it.

235

236 To explain this variation in individual growth rate, we hypothesized that different genera might
237 mutually influence each other's growth rate, either by competition or by cooperation. In order to
238 quantify the level of growth rate interdependencies we performed *in silico* knockouts for each
239 genus in each sample and tracked the change of growth rate for all remaining genera in the
240 sample (see Methods). Here we found that each individual genus' growth rate was impacted by
241 another genus in at least one of the 186 samples. As could be hypothesized for a set of bacteria
242 competing for the same resources, most interactions were competitive (red edges in Figure 3B).
243 However, we observed a distinct subset of bacteria that were interconnected by a large amount
244 of cooperative interactions (blue edges in Figure 3B). Strikingly, many of the bacterial genera
245 contained in the group have been associated with gut health or disease, such as Anaerostipes,
246 Blautia, Escherichia, Bacteroides and Eubacterium (5, 30–34).

247

248 Analysis of minimal exchanges reveals the metabolic consequences for the
249 host

250

251 One of the major modes of interaction between the gut microbiota and the host is by means of
252 consumption or production of the metabolite pool in the gut. We quantified this effect by
253 obtaining all import and export fluxes for each individual genus across all samples (12,460
254 exchange reactions) as well as metabolite exchanges between the microbiota and the gut
255 lumen (195 metabolites). This was done in the absence of a metabolic model for the
256 enterocytes, colonocytes or goblet cells due to the lack of a curated metabolic reconstruction
257 and validated objective function for those cells. Thus, the presented results should be seen as a
258 lower bound for the interaction of the microbiota with the gut. A unique set of exchange fluxes
259 was obtained by calculating the minimal medium, the set of exchange fluxes with smallest total
260 import flux for the growth rates obtained by cooperative trade-off (see Methods). This assumes
261 that the microbiota competes for resources with the gut or normal dilution and will thus favor an
262 efficient import that yields the maximum growth rate.

263

264 Even though the minimization of total import fluxes favors simpler media compositions most
265 samples showed a diverse consumption of metabolites from the gut, particularly using a wide
266 array of different carbon and nitrogen sources (see Figure 4A). There was a large set of
267 metabolites that were consumed across all samples but also a smaller set containing some
268 specific carbon sources such as Arabinogalactan and Rhamnogalacturonan derivatives and a
269 few selected amino acids such as Alanine and Cysteine. Also, all communities showed a net
270 anaerobic growth as would be expected in the gut.

271

272 Export fluxes in general were pretty sparse which could again be expected from the
273 minimization of import fluxes and the lack of the gut epithelium in the models (Figure 4A).
274 However, we observed a large array of metabolites that was produced by the microbiota and
275 secreted into the gut lumen. Those are always available to gut epithelium since they are a
276 byproduct of maximizing growth in the microbiota. The associated export fluxes were in general
277 much more sample-specific than imports. In particular we found a large set of metabolites that
278 was only produced by a small set of samples and included all the major short-chain fatty acids
279 (SCFAs) such as butyrate, acetate, propionate and its precursors which have been previously
280 implicated in intestinal health (1, 35, 36). SCFA production seemed to be dependent on the

281 consumption of a small set of starches, pectin and xylan (see Figure 4A). The overall production
282 capacity (total production flux across all genera in the sample) for the major SCFAs showed
283 large variations even in healthy individuals. Butyrate and propionate production capacities were
284 diminished by about 2-fold in individuals with type 1 diabetes and also slightly altered (non-
285 significant) in metformin negative individuals with type 2 diabetes (Figure 4B). However, most of
286 the produced SCFAs were also consumed by the microbiota leaving only a small net production
287 of SCFAs available for the host (at least in the absence of competition with the gut epithelium,
288 see Figure S2). We observed that this net production was completely abolished for all major
289 SCFAs in Danish metformin negative individuals with type 2 diabetes but was recovered in
290 Danish metformin positive individuals (Figure 4C). This means that overshoot SCFA production
291 is a common necessity from microbiota growth in healthy and metformin positive individuals but
292 not in metformin negative individuals. This is consistent with previous findings in Danish and
293 Chinese populations (3, 22, 37). However, we did not observe those effects in the samples from
294 Swedish individuals which had generally higher production rates of the major SCFAs and
295 showed only a slightly higher net production rate in metformin treated individuals (Figure 4C).

296
297 To visualize the structure of metabolite consumption by individual bacterial genera in the gut we
298 used t-SNE dimensionality reductions on the individual genus-specific import fluxes (38). This
299 showed a clear niche structure across samples where individual genera could usually be
300 identified by their particular set of import fluxes (Figure 5A). Given the association between
301 short chain fatty acids and disease progression we also tried to characterize the degree of
302 SCFA cycling in the microbiota. Here we observed that butyrate was almost exclusively formed
303 in an acetate-dependent manner from acetyl-CoA, which is the most prevalent pathway in
304 bacteria (39). This was enabled by an extensive cross-feeding between the genera in the
305 microbiota. Acetate was mainly produced by *Bacteroides* and metabolized by *Eubacterium* to
306 yield butyrate and propionate (Figure 5B). However, production of SCFAs was complemented
307 by several other genera generating a network of SCFA cycling within the microbiota. Other
308 bacteria could selectively substitute *Bacteroides* and *Eubacterium* in order to maintain
309 production of acetate and butyrate (Figure S3). Consequently, 20 bacterial genera showed
310 notable (total exchange flux > 0.5 mmol/h) cross-feeding of SCFAs (Figure 5B). Cycling of
311 SCFAs and downstream metabolites within the gut microbiota seemed to differ across
312 metabolites. For instance, acetate and lactate were both produced and consumed by more than
313 20 genera, whereas propionate and pyruvate were only produced by a few genera (7 and 2
314 genera respectively, Figure S3).

315

316 Finally, we aimed to quantify the impact that isolated interventions may have on the net
317 consumption or production of particular metabolites by the microbiota. For this we chose three
318 Swedish samples (normal, T2D metformin-, T2D metformin+) with the most diverse set of
319 imports (largest set of imported metabolites) and which did not produce butyrate in the non-
320 perturbed setting (optimization by cooperative trade-off, no optimization on import fluxes). The
321 impact of a particular intervention was then quantified by using the elasticity coefficients (40,
322 41), a dimensionless measure of how strongly a particular parameter affects a particular flux
323 (see Methods). The specific single target interventions we tested were either increasing the
324 availability of any single metabolite in the diet or increasing a single bacterial abundance in the
325 community. In general, we observed that the healthy individual showed lower elasticity
326 coefficients than the two type 2 diabetes samples which can be interpreted as a certain
327 robustness to changes (see Figure 6). Most interventions had a strong impact on the import
328 fluxes (consumption of metabolites, yellow dots in Figure 6) but not on the net export fluxes
329 (production of metabolites, brown dots in Figure 6). In particular there was no single intervention
330 that would increase net butyrate production in any of the three samples tested.

331

332

333 Methods

334 Data availability and reproducibility

335

336 All data to reproduce the manuscript, intermediate results as well as Python scripts to reproduce
337 the figures in this manuscript are available in a data repository at
338 https://github.com/resendislab/micom_study. Metagenomic reads for the 186 individuals were
339 obtained from the study of Pedersen et. al. and can be downloaded from the Sequence Read
340 Archive (<https://www.ncbi.nlm.nih.gov/sra>) with the SRA toolkit
341 (<https://www.ncbi.nlm.nih.gov/sra/docs/toolkitsoft/>). A full list of run accession IDs for the
342 individual samples is provided in the data repository (“samples.csv”). All algorithms and
343 methods used here were implemented in a Python package and can be easily applied to
344 different data sets. The Python package “micom” (microbial **co**mmunities) along with
345 documentation and installation instructions is available at <https://github.com/resendislab/micom>.
346 Micom is based on the popular COBRAPy Python package for the constraint-based modeling of

347 biological networks and is compatible with its API (42). The cooperative trade-off strategy as
348 described here was introduced to micom in version 0.9.0. The AGORA reference
349 reconstructions with an already applied average Western diet can be downloaded from
350 <https://vmh.uni.lu/#downloadview>. Several methods used in micom require an interior point
351 solver with capabilities for quadratic programming problems (QPs) for which there is currently
352 only commercial software available. Micom supports CPLEX (<https://cplex.org>) and Gurobi
353 (<https://gurobi.org>) both of which have free licenses for academic use. Intermediate results that
354 required those solvers are also provided in the data repository to permit reproduction of our
355 major conclusions.

356 Metagenomic shotgun data analysis

357 All metagenomic analyses were performed in R using an in-house pipeline which is available as
358 an open source package along with documentation at
359 <https://github.com/resendislab/microbiome>. Sample FASTQ files were downloaded using the
360 SRA toolkit and trimmed and filtered using the DADA2 “filter_and_trim” function (43) with a left
361 trimming of 10 bp, no right trimming, a quality cutoff of 10 and a maximum number of 2
362 expected errors under the Illumina model. Abundances across different taxa levels were then
363 obtained using SLIMM (23) which was chosen since it supported one of the largest references
364 (almost 5,000 reference bacterial genomes). In brief, all sample FASTQ files were first aligned
365 to the SLIMM reference using Bowtie2 saving the 60 best matches for each read. Taxa
366 abundance profiles were then obtained using SLIMM with the default parameters and
367 assembled into a single abundance file. Genus-level quantifications for each sample were then
368 matched to the AGORA models by their respective NCBI taxa id. The final quantification and
369 mapping is provided in the data repository (“genera.csv” at
370 https://github.com/resendislab/micom_study).

371 Strategies used in micom

372 Flux balance analysis obtains approximate fluxes for a given organism by assuming a steady
373 state for all fluxes in the biological system and optimizing an organism-specific biomass
374 reaction. Using the stoichiometric matrix S which contains reaction in its columns and
375 metabolites in its rows this can be formulated as a constrained linear programming problem for
376 the fluxes v_i (in mmol/[gDW h]):

377

378 *maximize* v_{bm}

379 *s. t.* $Sv = 0$

380 $lb_i \geq v_i \geq ub_i$

381

382 The biomass reaction v_{bm} is usually normalized such that it will produce 1g of biomass which
383 results in a unit 1/h corresponding to the growth rate μ of the organism. The upper and lower
384 bounds (lb_i and ub_i , respectively) impose additional thermodynamic constraints on the fluxes or
385 restrict exchanges with the environment (in the case of exchange fluxes). In order to describe a
386 community model containing several organisms each with a particular abundance a_i (in gDW)
387 one usually embeds each organism in an external compartment which represents the
388 community environment (for instance the gut lumen for models of the gut microbiota). Adding
389 exchanges for the environment compartment and exchanges between a particular organism and
390 the environment one obtains a community model with the following constraints:

391
$$\mu_c = \sum_i a_i \cdot \mu_i$$

392 *s. t.* $\forall i: Sv = 0$

393
$$\mu_i = v_i^{bm} \geq \mu_i^{min}$$

394
$$lb_i \geq v_i \geq ub_i$$

395
$$lb_i^{ex} \geq a_i \cdot v_i^{ex} \geq ub_i^{ex}$$

396
$$lb_i^m \geq v_i^m \geq ub_i^m$$

397 Here, a_i denotes the relative abundance of genus i , μ_i its growth rate, v_i^{bm} its biomass flux, μ_i^{min} a
398 user specified minimum growth rate, v_i^{ex} the exchange fluxes with the external environment, and
399 lb and ub the respective lower and upper bounds. Additionally, μ_c denotes the community
400 growth rate and v_i^m the exchanges between the entire community and the gut lumen. The
401 described constraints are identical to the ones employed in SteadyCom (18, 23). We assigned
402 an upper bound of 100 mmol/[gDW h] for the internal exchange fluxes v_i^{ex} . Assuming a total
403 microbiota biomass of 200 g and a representative bacterial cell dry weight of 2 pg (44), this
404 corresponds to a maximum import or export of more than 100,000 molecules/[cell s]. Diet
405 derived lower bounds with values smaller 10^{-6} mmol/[gDW h] were set to zero because they
406 would correspond to an exchange of less than a 1 molecule/[cell s]. Subpopulations with relative
407 abundances a_i smaller 10^{-4} were discarded since they would not be able to affect the external
408 metabolite levels in a significant way. Internal fluxes v_i received respective bounds of 1000.0 (or
409 0 if irreversible) making them essentially unbounded. The described constraints are applied to

410 all optimization problems in micom and will be further called the “community constraints”. It
411 should be noted that internal exchange fluxes v_i^{ex} have to be scaled by the abundance of the
412 respective sub-model when reporting to give the net exchange flux provided by the
413 subpopulation i .

414

415 The cooperative trade-off method consists of two sequential problems. First, maximize the
416 community growth rate μ_c to obtain μ_c^{max} . Using a user specified trade-off α now solve the
417 following quadratic minimization problem:

418
$$\text{minimize } \sum_i \mu_i^2$$

419
$$\text{s. t. } \mu_c \geq \alpha \cdot \mu_c^{\text{max}}$$

420 *and community constraints*

421

422 The knockout for a genus i was performed by setting all fluxes belonging to this genus along
423 with its exchanges with the external environment to zero ($lb=0$ and $ub=0$). This is followed by
424 running cooperative trade-off on the knockout model and comparing the growth rates after the
425 knockout with the ones without the knockout.

426 Solvers and Numerical stabilization

427 Most genome-scale metabolic models usually do not treat more than 10,000 variables in the
428 corresponding linear or quadratic programming problems. However, in microbial community
429 models we usually treat 10s to 100s distinct genome-scale models which makes the
430 corresponding problem much larger. Unfortunately, many open and commercial solvers have
431 difficulties solving problems of that scale, so we also implemented strategies to increase the
432 success rate of those optimizations. All linear and quadratic programming problems were solved
433 using interior point methods as those were much faster than simplex methods for problems with
434 more than 100,000 variables. Here, we used Cplex but also tested all methods with Gurobi.
435 Since growth rates tend to be small we also multiplied the objectives used in cooperative
436 tradeoff (maximization of community growth rate and minimization of regularization term) with a
437 scaling factor in order to avoid near-zero objective coefficients. A scaling factor in the order of
438 the largest constraint (1000.0) seemed to work well. Nevertheless, the default interior point
439 methods for quadratic problems in Cplex or Gurobi were usually not capable of solving the
440 minimization of the regularization term to optimality and usually failed due to numerical

441 instability. However, the solutions reported by the aborted optimization run were usually close to
442 the optimum but had the tendency to violate some numerically ill-conditioned constraints. To
443 alleviate this problem, we implemented a crossover strategy where we took the solution of the
444 numerically ill-conditioned quadratic interior point method as a candidate solution set μ_i^{ca} . Based
445 on that we now optimized the following linear programming problem in order to restore
446 feasibility:

$$447 \quad \text{maximize } \mu_c = \sum_i a_i \cdot \mu_i$$

$$448 \quad \text{s. t. } \mu_i \leq \mu_i^{ca}$$

449 *and community constraints*

450 Linear interior point methods are usually numerically stable so this linear programming problem
451 can usually be solved to optimality. The maximization together with the new constraints will
452 push the individual growth rates towards the candidate solution as long as it is numerically
453 feasible.

454

455 Additionally, we found that normalizing the import fluxes to the total community mass also
456 increased numerical instability since it leads to models where flux bounds varied up to ten
457 orders of magnitude. A more stable strategy was to apply unscaled import fluxes and rather
458 dividing all growth rates by the total community mass after optimization. Fluxes obtained this
459 way can either be interpreted as the total flux across the entire microbiota (in mmol/h, our
460 preference) or be scaled the same way to obtain fluxes per gDW of microbiota (in mmol gDW⁻¹
461 h⁻¹). In general, we divided the growth rates by community biomass of 200g as reported recently
462 (44) and interpreted fluxes as total fluxes within the microbiota (in mmol/h).

463 Minimal media and exchange fluxes

464 By convention micom formulates all exchange fluxes in the import direction so that all import
465 fluxes are positive and export fluxes are negative. Based on this, the minimal medium for a
466 community was obtained by minimizing the total import flux:

$$467 \quad \text{minimize } v_{tot} = \sum_i \{v_i^m, v_i^m > 0\}$$

$$468 \quad \text{s. t. } \forall i: \mu_i \geq \mu_i^{ct}$$

$$469 \quad \mu_c \geq \alpha \cdot \mu_c^{max}$$

470 *and community constraints*

471 Here μ_i^{ct} denotes the optimal genera growth rates obtained by cooperative trade-off. The
472 community exchanges were then obtained by extracting all v_i^{m} , whereas genus-specific
473 exchanges were given by all v_i^{ex} as defined earlier.

474

475

476 Single target intervention studies

477 We used elasticity coefficients (40, 41) to evaluate the sensitivity of exchange fluxes to changes
478 in exchange flux bounds (ergo diet changes) or changes in genus abundances. The logarithmic
479 formulation of elasticity coefficients is given by

480

$$481 \varepsilon_p^v = \frac{\partial \ln |v|}{\partial \ln |p|}$$

482

483 where v denotes the exchange flux of interest and p the changed parameter. Since the absolute
484 value removes information about the directionality of the flux this was logged separately to
485 maintain this information. We used a value of 0.1 as differentiation step size in log space which
486 which corresponds to a bound or abundance increase of about 10.5% in the native scale. To
487 enable efficient computation elasticity coefficients were grouped by parameter, cooperative
488 trade-off run once without modification, the parameter was increased, cooperative trade-off was
489 run again and differentiation was performed for all exchange fluxes at once.

490

491 Discussion.

492 There is a large amount of data on microbial abundances available today. This is mostly due to
493 the cost efficiency of abundance-based experiments such as 16S rRNA sequencing or shallow
494 shotgun sequencing (45). However, there is also a wide interest in extracting information from
495 abundance data that goes beyond differential abundance testing (46). Here, metabolic modeling
496 can be a valuable tool since it integrates a wide array of data. In particular it allows to integrate
497 genomic data in the individual species-level metabolic models, diet information in the form of
498 import flux bounds, and abundance data from metagenomic shotgun or marker gene
499 sequencing. This allows to generate mechanistic predictions concerning the metabolism of the

500 microbial community and its exchanges with the environment. However, the complexity of
501 metagenome-scale metabolic models brings additional problems such as the inability to identify
502 individual growth rates and slow computations. Here, we provided a strategy that alleviates
503 those limitations and allows for complex analysis of the community structure and its metabolic
504 consequences. Our regularization strategy allowed for a fast identification of unique sets of
505 individual growth rates which operate in biological realistic ranges. This assumed that the
506 microbiota will prefer enabling more species or genera to grow over maximizing the growth of
507 only a few. We feel that this assumption is supported by the observation that most microbial
508 communities are constituted by a large amount of species. Individual growth rates for bacterial
509 genera varied greatly across samples (Fig. 2) and were only weakly dictated by the genus'
510 abundance in the sample (Fig. 3A). It seems that the large variation of growth rates can be
511 explained by a dependency of the growth rate on the presence of other bacteria in the sample
512 (compare Fig. 3B). Thus, bacterial growth in the gut microbiota is not only dictated by
513 abundance but also by intra-microbiota interactions.

514

515 Using cooperative trade-off, we were able to estimate arising co-dependencies in 186
516 personalized community models. Cooperative effects were limited to a small set of genera that
517 are often associated with health or disease. The microbiota composition also has a strong
518 influence on the metabolites produced by the community and production of important
519 compounds such as butyrate is hardly affected by interventions once established. Additionally,
520 the predicted effects on SCFA production by the community fall in line with previous
521 observations and suggest a potential application of community models in order to predict the
522 metabolic impact of a particular microbiota composition in a personalized manner (22, 47). For
523 instance, we showed that the connection between butyrate production and microbiota growth is
524 fragile and forcing butyrate production to be a necessity of growth might be a robust strategy to
525 improve gut health. We furthermore predicted a complex system of SCFA cycling in the
526 microbiota which might serve to stabilize not only the overall production of SCFAs but also their
527 ratios. Experiments in rat and mouse models have shown that ratios between the three major
528 SCFAs help to control the fraction of goblet cells and underlie the maintenance and function of
529 colonocytes (48–50).

530

531 However, it should be noted that our predictions are limited by a variety of factors, for instance
532 the lack of metabolic models for the major cell types of the gut epithelium (especially goblet
533 cells, enterocytes and colonocytes) and sample-specific nutrition data. Thus, we feel that the

534 current major application for micom is to provide detailed functional hypothesis which can then
535 be validated experimentally. Here, we identified the potential major contributors to SCFA
536 production and cycling in the gut microbiota which may form the basis for identifying cross-
537 feeding mechanisms to validate *in vitro*.

538

539 We observed that changes in metabolism seemed to require rather large changes in the
540 community composition. Import fluxes varied only slightly across samples and most individual
541 genera formed distinct niches. Furthermore, small single target interventions only had a
542 substantial impact on the consumption rates of metabolites but could not affect the production of
543 metabolites by the community in a consistent manner (Figure 6). Still, export fluxes did vary
544 substantially across samples with different microbiota compositions (Figure 4A). In summary,
545 this suggests that changes in the production of metabolites by the microbiota require relatively
546 large-scale changes in the community and cannot be achieved by small-scale changes such as
547 changing a single diet component or increasing the abundance of a single bacterial genus. This
548 goes in line with the large success of fecal microbiota transplants (FMT) and we hope that the
549 methods introduced here will help to leverage affordable microbiome data in order to design
550 personalized intervention strategies. Additionally, the methods here extend to any ecosystem
551 containing several microbial species. As such micom can be used to perform computational
552 functional analysis for a wide class of microbial ecosystems.

553 Acknowledgements

554

555 ORA thank the financial support of an internal grant from the National Institute of Genomic
556 Medicine (INMEGEN/México).

557 Author contributions

558 CD developed/implemented the methods and performed the analysis. ORA developed the
559 methods and designed the meta-analysis. All authors wrote the manuscript.

560 Supplementary Material

561 All additional materials and data are available at https://github.com/resendislab/micom_study.


562

563

564

565

566 **Figures**



567


568 Figure 1: Regularization of growth rates. (A) Regularization values for a toy model of two identical *E. coli*
 569 subpopulations. Shown are two alternative solutions with different individual growth rates and the
 570 respective values of L1 and L2 regularization. Only L2 regularization favors one over the other and
 571 identifies the expected solution where both subpopulations grow with the same rate. (B) Effect of different
 572 trade-off values (fraction of maximum) on the distribution of individual genus growth rates. Zero growth
 573 rates were assigned a value of 10^{-16} which was smaller than the observed non-zero minimum. Growth
 574 rates smaller than 10^{-6} were considered to not represent growth. (C) Fraction of the overall number of
 575 genera that were able to grow under varying trade-off values. “None” indicates a model without
 576 regularization returning arbitrary alternative solutions. Growth rates assumed a total microbiota biomass
 577 of 200g for all samples (see Methods).

578

579

580

581




582

583 Figure 2: Non-zero growth rates ($> 10^{-6}$) across genera obtained by cooperative trade-off (50% maximum
 584 community growth rate). Each point denotes a growth rate in one of the 186 samples. Growth rates
 585 assumed a total microbiota biomass of 200g for all samples (see Methods).

586

587



588

589

590

591

592

593

594

595

596

597

598

599

600

601


602

603

604


605

Figure 3: Co-dependencies of growth rates. (A) Genera growth rates are slightly correlated on the log-log-scale (Pearson $R=0.69$, $n=39,815$). Shown is the density at each point with darker blue indicating higher density. Marginal density estimations are shown on the sides. (B) Growth rate interactions between genera as estimated by genera knockouts. Shown are only interaction that induce a growth rate change of at least 50% the observed maximum. Color of edges indicates strength (in %maximum growth rate change) and type of interaction. Red edges denote competition where one removal of one genus increases the growth rate of the other and blue edges denote cooperation where the removal of one genus lowers the growth rate of the other. Nodes are colored by the degree (number of edges) from lime (low degree) to dark blue (high degree).




606
607 Figure 4: Exchange fluxes of the microbiota across samples. Exchange fluxes were calculated as the
608 smallest set of import fluxes that could maintain the genera growth rates obtained by cooperative trade-
609 off. (A) Exchange fluxes across samples. Rows were normalized to their absolute maximum and colors
610 denote the strength and direction of exchange. Red denotes import fluxes (consumption of metabolites by
611 the community) and blue denotes export fluxes (production of metabolites by the community). (B)
612 Production capacities of the major SCFAs stratified by population. Fluxes denote totals of export fluxes
613 scaled by genus abundance (see Methods). (C) Net production rates of the major SCFAs stratified by
614 population. Fluxes denote the overall net production in the external medium/gut lumen (see Methods).

615
616
617
618




619
620 Figure 5: Metabolite usage across genera. (A) Import fluxes for each genus in each sample
621 were reduced to two dimensions using t-SNE. Each point denotes a genus in one sample and is
622 colored and named by its genus. (B) Genus-specific fluxes for the three major SCFAs. Shown
623 are only genera that show large total SCFA exchange fluxes (> 0.5 mmol/h). Dots denote
624 means across all samples and bars denote standard deviations. Fluxes are scaled by genus
625 abundances (see Methods) and directed towards imports. Thus, positive fluxes denote
626 consumption of the metabolite and negative fluxes secretion/export.


627
628
629




630
631 Figure 6: Strong interventions across three samples. Single target interventions and their effect
632 on exchange fluxes between the microbiota and gut lumen. Edges denote interventions and are
633 colored by their elasticity coefficient. Shown are only interactions and metabolites with an
634 elasticity coefficient larger one (high sensitivity to changed parameters). Environmental
635 parameters that were changed are indicated in green (microbial abundances) and gray (diet)
636 and their exchange fluxes are colored in yellow if the microbiota produces the corresponding
637 metabolite and in brown if the microbiota consumes the target metabolite.



638
639 Figure S1. Fraction of observed genera growing in each sample. Each dot denotes a single
640 sample. A trade-off of “none” means optimization without L2 regularization and only maximizing
641 the community growth rate.
642
643



644
 645 Figure S2. Consumption rates for the major SCFAs. Fluxes are given as total consumption in
 646 the microbiota. Each dot denotes a sample (n=186).
 647



648
 649 Figure S3. Genus-level exchange fluxes for major metabolites across all samples. Color bar
 650 denotes total fluxes (mmol/h). Blue denotes imports/consumption and red denotes
 651 secretion/export. Shown are only genera with notable contributions (total absolute flux > 0.5
 652 mmol/h).

653 References

- 654 1. Cho I, Blaser MJ. 2012. The human microbiome: at the interface of health and disease. *Nat*
655 *Rev Genet* 13:260–270.
- 656 2. Lewis JD, Chen EZ, Baldassano RN, Otley AR, Griffiths AM, Lee D, Bittinger K, Bailey A,
657 Friedman ES, Hoffmann C, Albenberg L, Sinha R, Compher C, Gilroy E, Nessel L, Grant A,
658 Chehoud C, Li H, Wu GD, Bushman FD. 2015. Inflammation, Antibiotics, and Diet as
659 Environmental Stressors of the Gut Microbiome in Pediatric Crohn’s Disease. *Cell Host*
660 *Microbe* 18:489–500.
- 661 3. Qin J, Li Y, Cai Z, Li S, Zhu J, Zhang F, Liang S, Zhang W, Guan Y, Shen D, Peng Y,
662 Zhang D, Jie Z, Wu W, Qin Y, Xue W, Li J, Han L, Lu D, Wu P, Dai Y, Sun X, Li Z, Tang A,
663 Zhong S, Li X, Chen W, Xu R, Wang M, Feng Q, Gong M, Yu J, Zhang Y, Zhang M,
664 Hansen T, Sanchez G, Raes J, Falony G, Okuda S, Almeida M, LeChatelier E, Renault P,
665 Pons N, Batto J-M, Zhang Z, Chen H, Yang R, Zheng W, Li S, Yang H, Wang J, Ehrlich SD,
666 Nielsen R, Pedersen O, Kristiansen K, Wang J. 2012. A metagenome-wide association
667 study of gut microbiota in type 2 diabetes. *Nature* 490:55–60.
- 668 4. Livanos AE, Greiner TU, Vangay P, Pathmasiri W, Stewart D, McRitchie S, Li H, Chung J,
669 Sohn J, Kim S, Gao Z, Barber C, Kim J, Ng S, Rogers AB, Sumner S, Zhang X-S, Cadwell
670 K, Knights D, Alekseyenko A, Bäckhed F, Blaser MJ. 2016. Antibiotic-mediated gut
671 microbiome perturbation accelerates development of type 1 diabetes in mice. *Nat Microbiol*
672 1:16140.
- 673 5. Duvallet C, Gibbons SM, Gurry T, Irizarry RA, Alm EJ. 2017. Meta-analysis of gut
674 microbiome studies identifies disease-specific and shared responses. *Nat Commun* 8:1784.
- 675 6. Xu Z, Malmer D, Langille MGI, Way SF, Knight R. 2014. Which is more important for

- 676 classifying microbial communities: who's there or what they can do? *ISME J* 8:2357–2359.
- 677 7. Langille MGI, Zaneveld J, Caporaso JG, McDonald D, Knights D, Reyes JA, Clemente JC,
678 Burkepille DE, Vega Thurber RL, Knight R, Beiko RG, Huttenhower C. 2013. Predictive
679 functional profiling of microbial communities using 16S rRNA marker gene sequences. *Nat*
680 *Biotechnol* 31:814–821.
- 681 8. Aßhauer KP, Wemheuer B, Daniel R, Meinicke P. 2015. Tax4Fun: predicting functional
682 profiles from metagenomic 16S rRNA data. *Bioinformatics* 31:2882–2884.
- 683 9. Bauer E, Thiele I. 2018. From Network Analysis to Functional Metabolic Modeling of the
684 Human Gut Microbiota. *mSystems* 3.
- 685 10. Heinken A, Sahoo S, Fleming RMT, Thiele I. 2013. Systems-level characterization of a
686 host-microbe metabolic symbiosis in the mammalian gut. *Gut Microbes* 4:28–40.
- 687 11. Resendis-Antonio O, Reed JL, Encarnación S, Collado-Vides J, Palsson BØ. 2007.
688 Metabolic reconstruction and modeling of nitrogen fixation in *Rhizobium etli*. *PLoS Comput*
689 *Biol* 3:1887–1895.
- 690 12. Orth JD, Thiele I, Palsson BØ. 2010. What is flux balance analysis? *Nat Biotechnol* 28:245–
691 248.
- 692 13. Lewis NE, Hixson KK, Conrad TM, Lerman JA, Charusanti P, Polpitiya AD, Adkins JN,
693 Schramm G, Purvine SO, Lopez-Ferrer D, Weitz KK, Eils R, König R, Smith RD, Palsson
694 BØ. 2010. Omic data from evolved *E. coli* are consistent with computed optimal growth
695 from genome-scale models. *Mol Syst Biol* 6:390.
- 696 14. Medlock GL, Carey MA, McDuffie DG, Mundy MB, Giallourou N, Swann JR, Kolling GL,
697 Papin JA. 2018. Inferring Metabolic Mechanisms of Interaction within a Defined Gut

- 698 Microbiota. *Cell Systems* 7:245–257.e7.
- 699 15. Long MR, Ong WK, Reed JL. 2015. Computational methods in metabolic engineering for
700 strain design. *Curr Opin Biotechnol* 34:135–141.
- 701 16. Zomorodi AR, Maranas CD. 2012. OptCom: a multi-level optimization framework for the
702 metabolic modeling and analysis of microbial communities. *PLoS Comput Biol* 8:e1002363.
- 703 17. Thompson LR, Sanders JG, McDonald D, Amir A, Ladau J, Locey KJ, Prill RJ, Tripathi A,
704 Gibbons SM, Ackermann G, Navas-Molina JA, Janssen S, Kopylova E, Vázquez-Baeza Y,
705 González A, Morton JT, Mirarab S, Zech Xu Z, Jiang L, Haroon MF, Kanbar J, Zhu Q, Jin
706 Song S, Kosciolk T, Bokulich NA, Lefler J, Brislawn CJ, Humphrey G, Owens SM,
707 Hampton-Marcell J, Berg-Lyons D, McKenzie V, Fierer N, Fuhrman JA, Clauset A, Stevens
708 RL, Shade A, Pollard KS, Goodwin KD, Jansson JK, Gilbert JA, Knight R, Earth
709 Microbiome Project Consortium. 2017. A communal catalogue reveals Earth’s multiscale
710 microbial diversity. *Nature* 551:457–463.
- 711 18. Chan SHJ, Simons MN, Maranas CD. 2017. SteadyCom: Predicting microbial abundances
712 while ensuring community stability. *PLoS Comput Biol* 13:e1005539.
- 713 19. The Human Microbiome Project Consortium. 2012. Structure, function and diversity of the
714 healthy human microbiome. *Nature* 486:207–214.
- 715 20. Engl HW, Hanke M, Neubauer A. 2000. *Regularization of Inverse Problems*. Springer
716 Science & Business Media.
- 717 21. Hoerl AE, Kennard RW. 1970. Ridge Regression: Biased Estimation for Nonorthogonal
718 Problems. *Technometrics* 12:55–67.
- 719 22. Forslund K, Hildebrand F, Nielsen T, Falony G, Le Chatelier E, Sunagawa S, Prifti E,

- 720 Vieira-Silva S, Gudmundsdottir V, Pedersen HK, Arumugam M, Kristiansen K, Voigt AY,
721 Vestergaard H, Hercog R, Costea PI, Kultima JR, Li J, Jørgensen T, Levenez F, Dore J,
722 MetaHIT consortium, Nielsen HB, Brunak S, Raes J, Hansen T, Wang J, Ehrlich SD, Bork
723 P, Pedersen O. 2015. Disentangling type 2 diabetes and metformin treatment signatures in
724 the human gut microbiota. *Nature* 528:262–266.
- 725 23. Dadi TH, Renard BY, Wieler LH, Semmler T, Reinert K. 2017. SLIMM: species level
726 identification of microorganisms from metagenomes. *PeerJ* 5:e3138.
- 727 24. Magnúsdóttir S, Heinken A, Kutt L, Ravcheev DA, Bauer E, Noronha A, Greenhalgh K,
728 Jäger C, Baginska J, Wilmes P, Fleming RMT, Thiele I. 2017. Generation of genome-scale
729 metabolic reconstructions for 773 members of the human gut microbiota. *Nat Biotechnol*
730 35:81–89.
- 731 25. Potra FA, Wright SJ. 2000. Interior-point methods. *J Comput Appl Math* 124:281–302.
- 732 26. Maurice CF, Haiser HJ, Turnbaugh PJ. 2013. Xenobiotics shape the physiology and gene
733 expression of the active human gut microbiome. *Cell* 152:39–50.
- 734 27. Gibson B, Wilson DJ, Feil E, Eyre-Walker A. 2018. The distribution of bacterial doubling
735 times in the wild. *Proc Biol Sci* 285.
- 736 28. Lagier J-C, Million M, Hugon P, Armougom F, Raoult D. 2012. Human gut microbiota:
737 repertoire and variations. *Front Cell Infect Microbiol* 2:136.
- 738 29. Koren O, Goodrich JK, Cullender TC, Spor A, Laitinen K, Bäckhed HK, Gonzalez A, Werner
739 JJ, Angenent LT, Knight R, Bäckhed F, Isolauri E, Salminen S, Ley RE. 2012. Host
740 remodeling of the gut microbiome and metabolic changes during pregnancy. *Cell* 150:470–
741 480.

- 742 30. Morgan XC, Tickle TL, Sokol H, Gevers D, Devaney KL, Ward DV, Reyes JA, Shah SA,
743 LeLeiko N, Snapper SB, Bousvaros A, Korzenik J, Sands BE, Xavier RJ, Huttenhower C.
744 2012. Dysfunction of the intestinal microbiome in inflammatory bowel disease and
745 treatment. *Genome Biol* 13:R79.
- 746 31. Brown K, DeCoffe D, Molcan E, Gibson DL. 2012. Diet-induced dysbiosis of the intestinal
747 microbiota and the effects on immunity and disease. *Nutrients* 4:1095–1119.
- 748 32. Bajaj JS, Hylemon PB, Ridlon JM, Heuman DM, Daita K, White MB, Monteith P, Noble NA,
749 Sikaroodi M, Gillevet PM. 2012. Colonic mucosal microbiome differs from stool microbiome
750 in cirrhosis and hepatic encephalopathy and is linked to cognition and inflammation. *Am J*
751 *Physiol Gastrointest Liver Physiol* 303:G675–85.
- 752 33. Chen W, Liu F, Ling Z, Tong X, Xiang C. 2012. Human intestinal lumen and mucosa-
753 associated microbiota in patients with colorectal cancer. *PLoS One* 7:e39743.
- 754 34. Murri M, Leiva I, Gomez-Zumaquero JM, Tinahones FJ, Cardona F, Soriguer F, Queipo-
755 Ortuño MI. 2013. Gut microbiota in children with type 1 diabetes differs from that in healthy
756 children: a case-control study. *BMC Med* 11:46.
- 757 35. Kinross JM, Darzi AW, Nicholson JK. 2011. Gut microbiome-host interactions in health and
758 disease. *Genome Med* 3:14.
- 759 36. Tan J, McKenzie C, Potamitis M, Thorburn AN, Mackay CR, Macia L. 2014. The role of
760 short-chain fatty acids in health and disease. *Adv Immunol* 121:91–119.
- 761 37. Tremaroli V, Bäckhed F. 2012. Functional interactions between the gut microbiota and host
762 metabolism. *Nature* 489:242–249.
- 763 38. Mahfouz A, van de Giessen M, van der Maaten L, Huisman S, Reinders M, Hawrylycz MJ,

- 764 Lelieveldt BPF. 2015. Visualizing the spatial gene expression organization in the brain
765 through non-linear similarity embeddings. *Methods* 73:79–89.
- 766 39. Vital M, Howe AC, Tiedje JM. 2014. Revealing the Bacterial Butyrate Synthesis Pathways
767 by Analyzing (Meta)genomic Data. *MBio* 5:5.
- 768 40. Savageau MA. 2010. *Biochemical Systems Analysis: A Study of Function and Design in*
769 *Molecular Biology*. CreateSpace.
- 770 41. Heinrich R, Rapoport TA. 1974. A Linear Steady-State Treatment of Enzymatic Chains.
771 General Properties, Control and Effector Strength. *Eur J Biochem* 42:89–95.
- 772 42. Ebrahim A, Lerman JA, Palsson BO, Hyduke DR. 2013. COBRApy: COncstraints-Based
773 Reconstruction and Analysis for Python. *BMC Syst Biol* 7:74.
- 774 43. Callahan BJ, McMurdie PJ, Rosen MJ, Han AW, Johnson AJA, Holmes SP. 2016. DADA2:
775 High-resolution sample inference from Illumina amplicon data. *Nat Methods* 13:581–583.
- 776 44. Sender R, Fuchs S, Milo R. 2016. Revised Estimates for the Number of Human and
777 Bacteria Cells in the Body. *PLoS Biol* 14:e1002533.
- 778 45. Hillmann B, Al-Ghalith GA, Shields-Cutler R, Zhu Q, Gohl D, Beckman KB, Knight R,
779 Knights D. 2018. Evaluating the information content of shallow shotgun metagenomics.
- 780 46. Gilbert JA, Blaser MJ, Gregory Caporaso J, Jansson JK, Lynch SV, Knight R. 2018.
781 Current understanding of the human microbiome. *Nat Med* 24:392–400.
- 782 47. Wu H, Esteve E, Tremaroli V, Khan MT, Caesar R, Mannerås-Holm L, Ståhlman M, Olsson
783 LM, Serino M, Planas-Fèlix M, Xifra G, Mercader JM, Torrents D, Burcelin R, Ricart W,
784 Perkins R, Fernández-Real JM, Bäckhed F. 2017. Metformin alters the gut microbiome of
785 individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of

- 786 the drug. *Nat Med* 23:850–858.
- 787 48. Wrzosek L, Miquel S, Noordine M-L, Bouet S, Chevalier-Curt MJ, Robert V, Philippe C,
788 Bridonneau C, Cherbuy C, Robbe-Masselot C, Langella P, Thomas M. 2013. *Bacteroides*
789 *thetaiotaomicron* and *Faecalibacterium prausnitzii* influence the production of mucus
790 glycans and the development of goblet cells in the colonic epithelium of a gnotobiotic model
791 rodent. *BMC Biol* 11:61.
- 792 49. Wong JMW, de Souza R, Kendall CWC, Emam A, Jenkins DJA. 2006. Colonic Health:
793 Fermentation and Short Chain Fatty Acids. *J Clin Gastroenterol* 40:235–243.
- 794 50. Donohoe DR, Collins LB, Wali A, Bigler R, Sun W, Bultman SJ. 2012. The Warburg Effect
795 Dictates the Mechanism of Butyrate-Mediated Histone Acetylation and Cell Proliferation.
796 *Mol Cell* 48:612–626.
- 797